Quoin Pharmaceuticals provides update on its development product portfolio

Quoin Pharmaceuticals (QNRX) provided an updated overview of its development product portfolio. The company’s lead product, QRX003 for Netherton Syndrome, continues to advance in two registrational clinical studies. The studies are being conducted at clinical sites in the US, Europe and the Middle East. It is anticipated that each study will recruit between 12 to 16 subjects, with full recruitment targeted for early to mid Q1 2026. QRX003 remains on track to potentially become the first approved treatment for NS and Quoin is targeting filing an NDA for regulatory approval in 2H 2026. Quoin plans to self-commercialize QRX003 in the US, Western Europe and Japan and has signed nine commercial partnerships covering 61 additional countries to support global access of the product once approved. Quoin’s topical rapamycin program, which is being developed under a research agreement with The School of Pharmacy at University College Cork in Ireland, continues to progress. The program targets rare and orphan skin diseases including microcystic lymphatic malformations, venous malformations, and angiofibromas. In light of the expected near-term completion of the QRX003 clinical program for NS, Quoin has discontinued the development of QRX007 for NS. QRX007 was being developed through Quoin’s research agreement with The Queensland University of Technology in Australia.